Free Trial
NASDAQ:CABA

Cabaletta Bio (CABA) Stock Price, News & Analysis

Cabaletta Bio logo
$1.44 -0.08 (-5.26%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.48 +0.05 (+3.13%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cabaletta Bio Stock (NASDAQ:CABA)

Key Stats

Today's Range
$1.43
$1.55
50-Day Range
$1.44
$2.48
52-Week Range
$0.99
$6.74
Volume
935,451 shs
Average Volume
1.15 million shs
Market Capitalization
$73.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.43
Consensus Rating
Buy

Company Overview

Cabaletta Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

CABA MarketRank™: 

Cabaletta Bio scored higher than 36% of companies evaluated by MarketBeat, and ranked 723rd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Cabaletta Bio has only been the subject of 3 research reports in the past 90 days.

  • Read more about Cabaletta Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Cabaletta Bio are expected to decrease in the coming year, from ($2.34) to ($2.82) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cabaletta Bio is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cabaletta Bio is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cabaletta Bio has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Cabaletta Bio's valuation and earnings.
  • Percentage of Shares Shorted

    12.89% of the outstanding shares of Cabaletta Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    Cabaletta Bio has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cabaletta Bio has recently increased by 16.58%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cabaletta Bio does not currently pay a dividend.

  • Dividend Growth

    Cabaletta Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.89% of the outstanding shares of Cabaletta Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    Cabaletta Bio has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cabaletta Bio has recently increased by 16.58%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    12 people have searched for CABA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    15 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cabaletta Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.25% of the stock of Cabaletta Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Cabaletta Bio's insider trading history.
Receive CABA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter.

CABA Stock News Headlines

One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
Cabaletta Bio Inc News (CABA) - Investing.com
Cabaletta Bio, Inc. (CABA) - Yahoo Finance
See More Headlines

CABA Stock Analysis - Frequently Asked Questions

Cabaletta Bio's stock was trading at $2.27 at the beginning of 2025. Since then, CABA stock has decreased by 36.6% and is now trading at $1.44.

Cabaletta Bio, Inc. (NASDAQ:CABA) released its quarterly earnings data on Wednesday, May, 21st. The company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.04.

Cabaletta Bio (CABA) raised $87 million in an IPO on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group acted as the underwriters for the IPO.

Cabaletta Bio's top institutional shareholders include Jennison Associates LLC (11.86%). Insiders that own company stock include Steven Nichtberger, Anup Marda, Gwendolyn Binder and Catherine Bollard.
View institutional ownership trends
.

Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cabaletta Bio investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), e.l.f. Beauty (ELF), Jabil (JBL) and Disc Medicine (IRON).

Company Calendar

Last Earnings
5/21/2025
Today
8/01/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CABA
CIK
1759138
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

High Price Target
$25.00
Low Price Target
$3.00
Potential Upside/Downside
+902.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$115.86 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-78.29%
Return on Assets
-65.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.96
Quick Ratio
3.96

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.12 per share
Price / Book
0.46

Miscellaneous

Outstanding Shares
50,740,000
Free Float
45,034,000
Market Cap
$73.07 million
Optionable
Optionable
Beta
2.74

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:CABA) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners